| Recruiting | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated Wit Acromegaly | Phase 3 | 2025-11-26 |
| Recruiting | A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Dose Healthy Participants | Phase 1 | 2025-06-18 |
| Recruiting | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acut Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2025-05-30 |
| Active Not Recruiting | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Cent Central Precocious Puberty | Phase 3 | 2024-07-31 |
| Active Not Recruiting | A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Prostate Cancer | Phase 2 | 2024-05-23 |
| Recruiting | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Gli Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III | Phase 1 / Phase 2 | 2023-05-15 |
| Active Not Recruiting | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer Tha Small Cell Lung Cancer Recurrent | Phase 1 | 2023-05-02 |
| Terminated | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2022-08-09 |
| Terminated | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participan Acromegaly, GEP-NET | Phase 1 | 2022-05-18 |
| Terminated | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors Adult Solid Tumor | Phase 1 | 2021-12-16 |
| Active Not Recruiting | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participa Advanced Solid Tumors | Phase 1 | 2021-11-05 |
| Completed | A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in He Healthy Volunteers | Phase 1 | 2021-08-02 |
| Recruiting | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2021-04-30 |
| Terminated | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2019-07-30 |
| Completed | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic D Solid Tumor | Phase 1 / Phase 2 | 2019-04-26 |
| Terminated | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) Solid Tumor | Phase 2 | 2019-03-22 |
| Terminated | Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Jo Bone or Joint Infection | Phase 2 | 2019-02-20 |
| Completed | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Carcinoma, Non-Small-Cell Lung, Neoplasms | Phase 1 | 2017-10-10 |
| Completed | A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects Healthy Participants | Phase 1 | 2017-06-14 |
| Completed | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants Wi Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2016-06-05 |
| Completed | Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replace Bone Diseases, Infectious | Phase 1 | 2016-04-01 |
| Completed | Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in H Healthy | Phase 1 | 2015-11-01 |
| Completed | Study of Debio 1450 for Bacterial Skin Infections Bacterial Infections | Phase 2 | 2015-05-01 |
| Completed | A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers Bacterial Infections | Phase 1 | 2014-08-01 |
| Completed | A Single Dose Study of Debio 1450 in Healthy Subjects Bacterial Infections | Phase 1 | 2014-06-01 |
| Completed | Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option Hepatitis C, Liver Disease | Phase 2 | 2014-03-01 |
| Completed | Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial Squamous Cell Carcinoma of the Head and Neck | N/A | 2013-10-01 |
| Completed | Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Hepatitis C, Liver Disease | N/A | 2013-10-01 |
| Completed | Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared t Kidney Failure, Chronic | Phase 1 | 2013-08-01 |
| Terminated | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alteratio Solid Tumours | Phase 1 | 2013-08-01 |
| Terminated | Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies Solid Tumors | Phase 1 | 2013-04-01 |
| Terminated | A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients Wit Non-small Cell Lung Cancer | Phase 1 | 2012-08-01 |
| Completed | Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Prostate Cancer | Phase 3 | 2012-07-01 |
| Completed | Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precoc Central Precocious Puberty | Phase 3 | 2012-04-01 |
| Terminated | Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C Hepatitis C | Phase 3 | 2012-03-01 |
| Completed | Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatiti Hepatitis C | Phase 3 | 2011-12-01 |
| Terminated | Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated f Hepatitis C | Phase 3 | 2011-12-01 |
| Completed | Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Com Hepatic Insufficiency | Phase 1 | 2011-03-01 |
| Completed | Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participan Hepatitis C | Phase 3 | 2011-03-01 |
| Completed | Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 T Hepatitis C, Chronic Pain | Phase 2 | 2010-10-01 |
| Completed | Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavi Hepatitis C | Phase 2 | 2010-08-01 |
| Completed | Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma Cancer, Neoplasms, Solid Tumors | Phase 1 | 2010-04-01 |
| Completed | Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphoma Cancer, Solid Tumors, Lymphoma | Phase 1 | 2010-03-29 |
| Withdrawn | Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients Heart Failure | Phase 2 | 2009-06-01 |
| Withdrawn | Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure Heart Failure | Phase 1 | 2009-06-01 |
| Completed | A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis Chronic Hepatitis C | N/A | 2009-01-01 |
| Completed | A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders Chronic Hepatitis C | Phase 2 | 2007-09-01 |
| Completed | Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease Moderate Alzheimer's Disease | N/A | 2007-02-01 |
| Completed | Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer Prostatic Neoplasm | Phase 3 | 2006-07-01 |
| Completed | Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients Fibrosis, Lung Disease, Respiratory Disorders | Phase 2 | 2006-07-01 |